Randomized phase II study of best available fluoropyrimidine compared with continuation of gemcitabine (Gem) monotherapy in patients with Gem-refractory pancreatic cancer.
Tatsuya Ioka
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Kazuhiro Katayama
No relevant relationships to disclose
Nobuko Ishida
No relevant relationships to disclose
Ryoji Takada
No relevant relationships to disclose
Takuo Yamai
No relevant relationships to disclose
Nobuyasu Fukutake
No relevant relationships to disclose
Reiko Ashida
No relevant relationships to disclose
Hiroyuki Uehara
No relevant relationships to disclose
Hiroaki Ohigashi
No relevant relationships to disclose
Hidenori Takahashi
No relevant relationships to disclose
Osamu Ishikawa
No relevant relationships to disclose